HIN
A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19. The trial, ACTIV-2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The therapeutic was developed by SAB Biotherapeutics, Inc. (Sioux Falls, South Dakota).
NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program is a public-private partnership to develop a coordinated research strategy for speeding development of the most promising treatments and vaccine candidates. ACTIV-2 is a master protocol designed for evaluating multiple investigational agents in adults with mild-to-moderate COVID-19 who are not hospitalized. Led by the NIAID-funded AIDS Clinical Trials Group (ACTG) and supported by PPD (Wilmington, North Carolina), a global contract research organization that is re
Large NIH clinical trial will test polyclonal antibody therapeutic for COVID-19
nih.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nih.gov Daily Mail and Mail on Sunday newspapers.
Vanderbilt Seeks Volunteers for COVID-19 Clinical Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Vanderbilt Seeks Volunteers for COVID-19 Clinical Trial
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
The new leader of the nation’s coronavirus fight has been battling diseases her whole career Laura Krantz © Kate Flock/MGH Dr. Rochelle Walensky.
The unit where Dr. Rochelle Walensky performed her residency, during the peak of the AIDS epidemic in Baltimore, held a standing memorial service every two weeks because so many of its patients were dying.
It was a grueling start to a medical career, when young trainees worked 100-hour weeks at Johns Hopkins Hospital, holding the hands of people succumbing to a virus for which there was not yet any treatment.
“In 1995 we told patients with AIDS they would, with certainty, die,” Walensky said in 2019 testimony before Congress. Since those early days, the physician has had a meteoric rise at Massachusetts General Hospital, including being appointed just the third chief and the first woman to lead the Division of Infectious Diseases since its inception in 1956.